Further, a systematic review has demonstrated that PD-L1 inhibitors have a slightly lower incidence of grade 3/4 immune-related pneumonitis as compared to PD-1 inhibitors3, while anti-PD-1 and anti-PD-L1 antibody monotherapy shows a similar clinical response in previously treated NSCLC patients4–7. This evidence concerns the gene CD274 and non-small cell lung carcinoma.